Y-mAbs Therapeutics Statistics
Share Statistics
Y-mAbs Therapeutics has 45.22M
shares outstanding. The number of shares has increased by 3.04%
in one year.
| Shares Outstanding | 45.22M |
| Shares Change (YoY) | 3.04% |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | 64.43% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,594 |
| FTD / Avg. Volume | 0.42% |
Short Selling Information
The latest short interest is 3.07M, so 6.85% of the outstanding
shares have been sold short.
| Short Interest | 3.07M |
| Short % of Shares Out | 6.85% |
| Short % of Float | 8.22% |
| Short Ratio (days to cover) | 9.97 |
Valuation Ratios
The PE ratio is -11.7 and the forward
PE ratio is -4.49.
Y-mAbs Therapeutics's PEG ratio is
-0.32.
| PE Ratio | -11.7 |
| Forward PE | -4.49 |
| PS Ratio | 3.96 |
| Forward PS | 1.5 |
| PB Ratio | 3.77 |
| P/FCF Ratio | -22.09 |
| PEG Ratio | -0.32 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Y-mAbs Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.16 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $843,125 |
| Profits Per Employee | $-285,250 |
| Employee Count | 104 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.11 |
Taxes
| Income Tax | -146K |
| Effective Tax Rate | 0.49% |
Stock Price Statistics
The stock price has increased by -76.23% in the
last 52 weeks. The beta is 0.7, so Y-mAbs Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -76.23% |
| 50-Day Moving Average | 4.81 |
| 200-Day Moving Average | 9.6 |
| Relative Strength Index (RSI) | 41.22 |
| Average Volume (20 Days) | 375,268 |
Income Statement
In the last 12 months, Y-mAbs Therapeutics had revenue of 87.69M
and earned -29.67M
in profits. Earnings per share was -0.67.
| Revenue | 87.69M |
| Gross Profit | 72.43M |
| Operating Income | -31.2M |
| Net Income | -29.67M |
| EBITDA | -31.2M |
| EBIT | -31.2M |
| Earnings Per Share (EPS) | -0.67 |
Full Income StatementBalance Sheet
The company has 67.23M in cash and 820K in
debt, giving a net cash position of 66.41M.
| Cash & Cash Equivalents | 67.23M |
| Total Debt | 820K |
| Net Cash | 66.41M |
| Retained Earnings | -487.14M |
| Total Assets | 119.9M |
| Working Capital | 74.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -15.71M
and capital expenditures 0, giving a free cash flow of -15.71M.
| Operating Cash Flow | -15.71M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.71M |
| FCF Per Share | -0.35 |
Full Cash Flow StatementMargins
Gross margin is 82.61%, with operating and profit margins of -35.58% and -33.83%.
| Gross Margin | 82.61% |
| Operating Margin | -35.58% |
| Pretax Margin | -34% |
| Profit Margin | -33.83% |
| EBITDA Margin | -35.58% |
| EBIT Margin | -35.58% |
| FCF Margin | -17.92% |
